Debate: Hong Kong’s Cancer Research Tie‑Ups — Crisis, Opportunity, or Both?
On September 12, 2024, Dr. Li Wei, head of Hematology at Peking Union Medical College, delivered a keynote at the Hong Kong International Medical Conference, urging the city to strengthen research links with mainland China. His call follows a pilot CAR‑T therapy trial in Hong Kong that showed promising survival rates for patients with relapsed acute lymphoblastic leukemia. If Hong Kong becomes a bridge, it could accelerate access to cutting‑edge therapies for millions across China. The proposal has sparked debate among policymakers and researchers alike.
What Happened
Dr. Li Wei, the senior hematologist at Peking Union Medical College, spoke at the Hong Kong International Medical Conference on September 12, 2024. In a 30‑minute address, he outlined a vision for Hong Kong to become a central hub for translational cancer research between the mainland and the global scientific community. He cited the 2024 National Cancer Research Initiative, which aims to double funding for oncology research across China, and highlighted Hong Kong’s strategic position as a gateway to international markets. Dr. Li referenced a recent pilot clinical trial conducted in Hong Kong’s Kowloon Hospital, where a CAR‑T therapy targeting CD19‑positive leukemia achieved an overall survival rate of 78% at 12 months, surpassing mainland averages. He emphasized that 60% of Hong Kong’s biotech funding originates from mainland investors, yet the city lacks formal mechanisms for joint research and data sharing. Dr. Li proposed establishing a joint research consortium between the Hong Kong Cancer Research Institute (HKCRI) and the Shenzhen Institute of Hematology, with a shared data‑analysis platform to expedite clinical trials. The source for this account is an interview with Dr. Li via the South China Morning Post (SCMP).
Why It Matters
The proposal has significant implications for ordinary patients in both Hong Kong and mainland China. Faster integration of research findings could reduce the time between a new therapy’s approval and its availability in Hong Kong’s public hospitals, potentially lowering out‑of‑pocket costs for families. Moreover, the collaborative model could attract global pharmaceutical companies to set up regional R&D centers, creating high‑skill jobs and boosting the local economy. On a policy level, the initiative touches on the delicate balance of One Country, Two Systems; expanding research ties must navigate differing regulatory frameworks for clinical trials and data protection. Economically, the biotech sector in Hong Kong grew 15% in
Despite Hong Kong’s reputation as a financial gateway, more than 40 % of its biotech patents in the past five years were filed by mainland Chinese researchers who chose Hong Kong’s IP courts for faster adjudication.

